Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines
- Author:
Ji Geun YOO
1
;
Sung Jong LEE
;
Eun Ji NAM
;
Jae Hong NO
;
Jeong Yeol PARK
;
Jae Yun SONG
;
So-Jin SHIN
;
Bo Seong YUN
;
Sung Taek PARK
;
San-Hui LEE
;
Dong Hoon SUH
;
Yong Beom KIM
;
Taek Sang LEE
;
Jae Man BAE
;
Keun Ho LEE
Author Information
- Publication Type:Practice Guideline
- From:Journal of Gynecologic Oncology 2024;35(2):e44-
- CountryRepublic of Korea
- Language:English
- Abstract: This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on version 4.0 released in 2020. Each key question was developed by focusing on recent notable insights and crucial contemporary issues in the field of cervical cancer. These questions were evaluated for their significance and impact on the current treatment and were finalized through voting by the development committee. The selected key questions were as follows: the efficacy and safety of immune checkpoint inhibitors as firstor second-line treatment for recurrent or metastatic cervical cancer; the oncologic safety of minimally invasive radical hysterectomy in early stage cervical cancer; the efficacy and safety of adjuvant systemic treatment after concurrent chemoradiotherapy in locally advanced cervical cancer; and the oncologic safety of sentinel lymph node mapping compared to pelvic lymph node dissection. The recommendations, directions, and strengths of this guideline were based on systematic reviews and meta-analyses, and were finally confirmed through public hearings and external reviews. In this study, we describe the revised practice guidelines for the management of cervical cancer.
